Long-Term Efficacy and Tolerability of Abdominal Once-Yearly Histrelin Acetate Subcutaneous Implants in Patients with Advanced Prostate Cancer

<div>Mean serum prostate-specific antigen (PSA,  <i>μ</i>g/L) levels in patients after receiving once-yearly histrelin acetate implants for 240 weeks. The error bars represent the standard error of the mean (SEM).</div>

Prostate Cancer

fig2

Figure 2

Figure 2: Long-Term Efficacy and Tolerability of Abdominal Once-Yearly Histrelin Acetate Subcutaneous Implants in Patients with Advanced Prostate Cancer 

Figure 2 | Long-Term Efficacy and Tolerability of Abdominal Once-Yearly Histrelin Acetate Subcutaneous Implants in Patients with Advanced Prostate Cancer 